Source: Forbes
“The Federal Trade Commission on Friday sued three of the largest pharmacy benefit managers alleging the companies — which manage about 80% of prescriptions in the U.S. — have driven up the price of insulin, months after the agency released findings from an investigation detailing the firms’ business practices. UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts have created a ‘perverse’ drug rebate system that has ‘artificially inflated’ the price of insulin, the FTC alleges.” (09/20/24)